Abacus FCF Advisors LLC Acquires New Stake in DaVita Inc. $DVA

Key Points

• Abacus FCF Advisors LLC acquired 39,534 shares of DaVita Inc. stock, valued at approximately $5.6 million, marking a new stake in the company.
• Insider James O. Hearty sold 2,351 shares at an average price of $150.00, reducing his ownership in DaVita by 8.28%.
• DaVita reported a $2.95 EPS for the quarter, exceeding analysts' estimates and reflecting a 6.1% year-over-year revenue increase.

Abacus FCF Advisors LLC purchased a new position in shares of DaVita Inc. (NYSE:DVA - Free Report) during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund purchased 39,534 shares of the company's stock, valued at approximately $5,632,000. Abacus FCF Advisors LLC owned approximately 0.05% of DaVita at the end of the most recent quarter.

Several other hedge funds also recently made changes to their positions in DVA. Wedge Capital Management L L P NC grew its position in DaVita by 3.3% during the second quarter. Wedge Capital Management L L P NC now owns 268,444 shares of the company's stock valued at $38,240,000 after purchasing an additional 8,538 shares in the last quarter. Sovran Advisors LLC acquired a new position in DaVita during the 2nd quarter valued at $472,000. Strs Ohio acquired a new position in DaVita during the 1st quarter valued at $1,429,000. Bayforest Capital Ltd increased its holdings in DaVita by 331.1% in the 1st quarter. Bayforest Capital Ltd now owns 3,259 shares of the company's stock valued at $499,000 after buying an additional 2,503 shares during the period. Finally, MBB Public Markets I LLC bought a new stake in DaVita in the 1st quarter valued at $317,000. Institutional investors and hedge funds own 90.12% of the company's stock.

Analysts Set New Price Targets

A number of brokerages have commented on DVA. Wall Street Zen raised shares of DaVita from a "hold" rating to a "buy" rating in a report on Saturday, September 13th. Bank of America cut their price target on shares of DaVita from $145.00 to $140.00 and set an "underperform" rating on the stock in a research report on Wednesday, September 10th. Barclays lowered their target price on DaVita from $169.00 to $160.00 and set an "equal weight" rating for the company in a research note on Thursday, August 7th. Finally, Truist Financial set a $148.00 target price on DaVita in a research note on Friday, August 8th. Three research analysts have rated the stock with a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, the company has a consensus rating of "Reduce" and a consensus target price of $158.00.

DaVita Price Performance

Shares of DVA traded up $1.42 during trading hours on Tuesday, reaching $132.57. 284,082 shares of the company's stock traded hands, compared to its average volume of 858,576. The stock has a market cap of $9.48 billion, a PE ratio of 13.03, a price-to-earnings-growth ratio of 0.93 and a beta of 1.13. The company has a current ratio of 1.39, a quick ratio of 1.34 and a debt-to-equity ratio of 23.18. DaVita Inc. has a 12 month low of $126.07 and a 12 month high of $179.60. The firm's 50 day simple moving average is $136.91 and its 200-day simple moving average is $140.91.

DaVita (NYSE:DVA - Get Free Report) last announced its quarterly earnings data on Tuesday, August 5th. The company reported $2.95 earnings per share for the quarter, beating analysts' consensus estimates of $2.70 by $0.25. The company had revenue of $3.38 billion for the quarter, compared to analysts' expectations of $3.36 billion. DaVita had a return on equity of 369.39% and a net margin of 6.35%.DaVita's revenue for the quarter was up 6.1% compared to the same quarter last year. During the same period last year, the firm posted $2.00 EPS. DaVita has set its FY 2025 guidance at 10.200-11.300 EPS. Equities analysts expect that DaVita Inc. will post 10.76 EPS for the current year.

Insider Buying and Selling

In other DaVita news, insider James O. Hearty sold 2,351 shares of the business's stock in a transaction on Wednesday, July 23rd. The stock was sold at an average price of $150.00, for a total value of $352,650.00. Following the sale, the insider directly owned 26,038 shares of the company's stock, valued at approximately $3,905,700. The trade was a 8.28% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Company insiders own 1.50% of the company's stock.

DaVita Company Profile

DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.